RSPH9

Across TCGA pan-cancer cohorts, RSPH9 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated RSPH9 data layer compared with 1 for mutation status and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RSPH9 RNA is associated with better overall survival. In most high-consensus cancer types, elevated RSPH9 expression acts as an unfavorable survival marker, although some lineages such as LUAD and THCA show a favorable association.

LUAD, LGG, and ESCA are the cancer types where RSPH9 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.782	0.550	<.001	76	view →
LGG	OS	Median	All	0.716	0.899	<.001	54	view →
ESCA	DFS	Tertile	III,IV	0.269	0.612	.001	39	view →
LIHC	DFS	Median	All	0.470	0.608	.001	38	view →
KICH	OS	Tertile	All	0.740	1.000	.008	29	view →
COAD	DFS	Tertile	II,III,IV	0.389	0.588	.008	27	view →
THCA	DFS	Tertile	All	0.910	0.737	<.001	26	view →
UVM	DFS	Quartile	II,III,IV	0.452	0.894	.005	26	view →
ACC	DFS	Quartile	All	0.271	0.747	.002	22	view →
PAAD	DFS	Tertile	All	0.423	0.181	.005	21	view →
LAML	DFS	Median	All	0.456	0.687	.026	14	view →
MESO	DFS	Tertile	II,III,IV	0.262	0.452	.025	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

RSPH9–LUAD (OS)

Open the LUAD breakdown →